Acer Medical Inc (6857) Fair Value & Analysis
Healthcare · TW · Market cap 1.5B TWD
Fair value as of: Jun 24, 2026
Analysis
Acer Medical Inc (6857) currently trades at 94.00 TWD, while our model-based Fair Value estimate is 32.50 TWD — implying the stock looks roughly 65.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Acer Medical Inc. offers artificial intelligence, clinical data, and software for healthcare sector. It offers VeriSee DR, an AI-assisted diagnostic software for diabetic retinopathy identification; VeriSee AMD, an AI-assisted screening software for age-related macular degeneration identification; and VeriOsteo OP, an AI-assisted screening software for bone mineral density abnormalities. Acer Medical Inc. was founded in 2018 and is based in New Taipei City, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Acer Medical Inc (6857) undervalued?
What is the fair value of 6857?
What is the quality score of 6857?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.